Last reviewed · How we verify
Valsartan, Enalapril
Valsartan and Enalapril, marketed by the University of Vigo, are established treatments in the cardiovascular space with a key composition patent expiring in 2028. The drugs benefit from a well-documented mechanism and a strong market presence, positioning them as reliable options for primary indications. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Valsartan, Enalapril |
|---|---|
| Sponsor | University of Vigo |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The COVID-RASi Trial (COVID-19) (PHASE3)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC (PHASE4)
- An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan
- Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction (PHASE4)
- Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
- Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Valsartan, Enalapril CI brief — competitive landscape report
- Valsartan, Enalapril updates RSS · CI watch RSS
- University of Vigo portfolio CI